Loading
Life sciences · Journal article
Cardiology in Review · November 3, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Glucagon-like peptide-1 receptor agonists have transformed the treatment of type 2 diabetes and obesity and have more recently demonstrated clinically important effects across the cardiometabolic spectrum, including metabolic dysfunction–associated steatotic liver disease, metabolic dysfunction–associated steatohepatitis, and atherosclerotic cardiovascular disease. Earlier cardiovascular outcome trials established reductions in major adverse cardiovascular events by way of injectable forms in patients with diabetes, while newer evidence has expanded these findings to oral semaglutide and to other patient populations. This review summarizes the hepatic, cardiovascular, and heart-failure evidence for glucagon-like peptide-1 receptor agonists–based therapies and discusses remaining clinical uncertainties and future directions.